Department of Pharmaceutics, Virginia Commonwealth University, 1112 East Clay Street, Richmond, VA 23298, USA.
Ameritox LLC, Research and Development Department, 486 Gallimore Dairy Road, Greensboro, NC 27409, USA.
J Anal Toxicol. 2022 Oct 14;46(8):905-910. doi: 10.1093/jat/bkac043.
Duloxetine, known by its brand name, CymbaltaTM, is a selective serotonin and norepinephrine reuptake inhibitor used to treat major depressive disorders. Determination of patient compliance for duloxetine is typically determined through medication possession ratio (MPR) or plasma concentrations. The purpose of this paper was to characterize normal urinary duloxetine concentrations in patients prescribed duloxetine to monitor patient adherence. Patient data collected from routine screens for duloxetine concentrations in urine were included in this study. Inclusion criteria consisted of patients who were prescribed duloxetine and (i) tested positive for duloxetine, (ii) tested negative for illicit substances and (iii) included creatinine, age and duloxetine dose administered. Of the 5,592 patient urines screened, 2,004 of the results fit into the inclusion criteria. Positive urine concentrations of duloxetine ranged from 50 to 2,722 ng/mL. Duloxetine urine concentrations were normalized to creatinine and dose further characterized by sex, age, body mass index (BMI) and dose in milligrams. Sample distribution included urines collected from 1,487 females and 517 males. The age range of the specimen donors was between 15 and 90 years old with an average age of 52. BMI levels ranged from 13.9 (underweight) to 88.1 (obese), with the average BMI being 33.5. The most common dose of duloxetine prescribed was a daily, oral dose of 60 mg. Analysis of the normalized, transformed creatinine concentrations showed that there was a significant statistical difference (P < 0.05) in the urinary duloxetine concentrations by sex and by dose (mg). Female patients further showed a statistical difference in urinary duloxetine concentration in age groups 18-64 and 64 and older. By characterizing urinary duloxetine concentrations in patients prescribed the medication, normalized distributions of data ranges have been established. These data ranges for urinary duloxetine concentrations can be used to determine patient compliance with duloxetine in routine, clinical samples.
度洛西汀,商品名为欣百达(CymbaltaTM),是一种选择性 5-羟色胺和去甲肾上腺素再摄取抑制剂,用于治疗重度抑郁症。度洛西汀患者用药依从性的测定通常通过药物持有率(MPR)或血浆浓度来确定。本文的目的是描述服用度洛西汀的患者的正常尿液中度洛西汀的浓度,以监测患者的依从性。本研究纳入了从常规尿液中检测度洛西汀浓度的患者数据。纳入标准包括:开度洛西汀处方的患者,(i)度洛西汀检测阳性,(ii)尿液中未检出非法药物,(iii)包括肌酐、年龄和度洛西汀剂量。在筛查的 5592 份患者尿液中,有 2004 份结果符合纳入标准。尿液中度洛西汀的阳性浓度范围为 50 至 2722ng/ml。度洛西汀尿液浓度用肌酐和剂量进行归一化,并进一步根据性别、年龄、体重指数(BMI)和剂量(毫克)进行特征描述。样本分布包括 1487 名女性和 517 名男性的尿液。标本供体的年龄范围在 15 至 90 岁之间,平均年龄为 52 岁。BMI 水平从 13.9(体重不足)到 88.1(肥胖),平均 BMI 为 33.5。最常见的度洛西汀处方剂量是每日口服 60mg。对归一化、转换后的肌酐浓度进行分析显示,度洛西汀浓度在性别和剂量(mg)方面存在显著的统计学差异(P<0.05)。女性患者在 18-64 岁和 64 岁及以上年龄组中进一步显示出度洛西汀尿液浓度的统计学差异。通过描述服用药物的患者的尿液中度洛西汀浓度,建立了数据范围的归一化分布。这些度洛西汀尿液浓度数据范围可用于在常规临床样本中确定患者对度洛西汀的依从性。